While the relationship between Alzheimer’s and cardiovascular problems such as hypertension and diabetes remains complicated, a history of stroke is said to double the risk of late-onset AD.
In a validation study, three common software packages produced excessive false positives, but initial stories about previous suspect data might have been overblown.
BACE inhibitors are shaping up; pyroglutamate Aβ antibody clears plaques without ARIA, but immune reaction raises a flag.
Scientists report a way to stop transcription of the repeat expansion, leaving the normal gene alone.
Researchers at AAIC discussed technical limitations of current tracers and ways to improve the signal. A new ligand debuted that may be more specific for tangles.
Researchers at AAIC presented congruent data on the place tau tangles take in AD progression, and their close correlation with cognitive decline.
Profile matches Braak staging regions, suggesting those areas are particularly susceptible to AD pathology.
Sequencing the protein-coding DNA regions of more than 60,000 people sheds light on disease-causing mutations.
Concerns about research reproducibility are leading scientists to question their methods and adopt more rigorous standards. Case in point: A recent validation study of task-based fMRI found that software packages commonly used to analyze the data produce too many false positives. This implies that some fMRI findings in the literature may be erroneous, although initial news stories exaggerated the extent of the problem. Software developers are now revising their programs to correct the issue.
Researchers at AAIC presented a wealth of tau PET data from longitudinal and cross-sectional studies, all of which reinforced the notion that tangles spread only in the presence of amyloid. Regional tangles also consistently correlated with local neurodegeneration, as well as overall cognitive decline. Other talks discussed how to improve the tau PET signal-to-noise ratio and identified sources of off-target binding. Merck debuted a new tracer, which appears to bind more specifically to tau than other tracers in development.
Why do some regions of the brain fall prey to the deadly pathology of neurodegenerative disease, while others nearby sit unscathed? In a new study, researchers report that areas of the brain that take the first fall in Alzheimer’s disease express high levels of genes known to promote protein aggregation, and lower levels of genes that control it. This AD-ready expression signature appeared in healthy brains, yet mapped to Braak staging regions associated with disease. The findings suggest that problems with protein housecleaning may open the door to neurodegeneration.
- Einar Sigurdsson and Ayodeji Asuni on Antibody-Mediated Targeting of Tau In Vivo Does Not Require Effector Function and Microglial Engagement.
- Marco Cecchi on Staging of Alzheimer’s, the Second: Neurodegeneration Does Not Equal Tauopathy
- Takaomi Saido on New Ways to Target Aβ and BACE Show Promising Phase 1 Data
- Mark Jenkinson on Software Flaw Casts Doubt on Past Task fMRI Studies
- Prashanthi Vemuri on Software Flaw Casts Doubt on Past Task fMRI Studies
- Jeffrey D. Rothstein on Tackling Mutant C9ORF72 Transcripts at the Source
- Brian Gordon on Improving Tau PET: In Search of Sharper Signals
- Gil Rabinovici on Improving Tau PET: In Search of Sharper Signals
- Patrik Brundin on Aggregation-Prone Gene Expression Signature Mapped in Brain
- Colin Masters on Aggregation-Prone Gene Expression Signature Mapped in Brain
- Bradley Hyman on Aggregation-Prone Gene Expression Signature Mapped in Brain
- Bruno Vellas on Less Salmon, More Plaques? Link Between Omega-3s and Aβ Reinvigorates Fish Oil Debate
- Frederic Calon on Less Salmon, More Plaques? Link Between Omega-3s and Aβ Reinvigorates Fish Oil Debate
- Bruce Kagan on Brain Imaging Suggests Aβ Unleashes the Deadly Side of Tau
- Karen Hsiao Ashe on New APP Antibodies Expose Variation in Mouse Models of AD
- Christopher Rowe on Brain Imaging Suggests Aβ Unleashes the Deadly Side of Tau
- Tsuneya Ikezu on No Special Glasses Needed: Three-Dimensional Views of Tau and Aβ in the Brain
- Ian McKeith on Brain Atrophy Patterns Support Distinct Subtypes of Frontotemporal Dementia
- David M.A. Mann on Brain Atrophy Patterns Support Distinct Subtypes of Frontotemporal Dementia
- Christian Holscher on In First Phase 3 Trial, the Tau Drug LMTM Did Not Work. Period.
- Dietmar Thal on No Special Glasses Needed: Three-Dimensional Views of Tau and Aβ in the Brain